FDA Grants Fast Track to Elunetirom for Bipolar Depression
Autobahn Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to elunetirom, the company’s lead investigational therapy for the adjunctive treatment of depressive episodes associated with bipolar I and bipolar II disorder in adults, marking a regulatory milestone for a treatment aimed at addressing significant unmet needs in psychiatric care.
Elunetirom is an oral, once-daily, brain-penetrant therapy designed to target central nervous system thyroid hormone receptors (CNS-TR). The investigational drug is being developed as an add-on treatment for bipolar depression and major depressive disorder (MDD), conditions where many patients continue to experience inadequate symptom relief despite available medications.
The Fast Track designation, granted by the FDA to therapies intended to treat serious conditions and fill unmet medical needs, is expected to support closer communication with regulators and potentially accelerate the clinical development and review process if the treatment demonstrates promising results.
Autobahn Therapeutics said the designation reflects recognition of elunetirom’s potential to offer a differentiated treatment approach for bipolar depression, an area where therapeutic innovation has remained limited for decades.
Bipolar depression affects an estimated seven million adults in the United States and is considered among the most disabling psychiatric conditions. Patients frequently experience prolonged depressive episodes that significantly impair quality of life, work productivity, and daily functioning. According to the company, individuals with bipolar depression lose more than one month of work on average each year due to the burden of illness.
Despite the availability of multiple therapies, more than half of patients fail to achieve adequate symptom control. Existing treatments are often associated with limited effectiveness or difficult side effects, including weight gain, sexual dysfunction, metabolic complications, and movement disorders, creating challenges for long-term adherence and treatment success.
Alida Barry, vice president and head of regulatory affairs at Autobahn Therapeutics, described the FDA decision as an important advancement in efforts to bring a new treatment option to patients living with bipolar depression. She noted that Fast Track designation is intended for investigational medicines that may provide substantial benefits compared with currently available therapies for serious conditions with unmet medical needs.
Company executives emphasized that elunetirom is intended to represent a new mechanism of action in neuropsychiatric treatment by targeting thyroid hormone receptor signaling in the brain, rather than relying on traditional approaches used in antidepressants or antipsychotic therapies.
Kevin Finney, president and chief executive officer of Autobahn Therapeutics, said the standard of care for bipolar depression has changed little in recent decades, forcing patients to choose between inadequate symptom relief and burdensome side effects. He added that the company views the designation as an important step in its broader mission to improve treatment options for serious neuropsychiatric disorders and potentially reshape care for millions of people affected by depressive illnesses.
The company is currently evaluating elunetirom in an ongoing Phase 2 AMPLIFY-BD clinical trial for adjunctive bipolar depression, with topline data expected in the second quarter of 2026. In parallel, Autobahn is also studying the therapy as an adjunctive treatment for major depressive disorder through its Phase 2 AMPLIFY trial, where topline results are anticipated in the third quarter of 2026.
If successful, the program could position elunetirom as a novel treatment option in a therapeutic area where patients and physicians continue to seek safer and more effective alternatives to conventional therapies.